BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) has announced that a poster highlighting pre-clinical data on its coronavirus (COVID-19) vaccine candidate BVX-0320, will be presented at a joint three-day virtual conference of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) and the World Health Organization (WHO), starting on October 19, 2021.
The Vancouver-based biotechnology company is leveraging its haptenized antigen technology platforms to develop vaccines to potentially treat viral infections such as SARS-CoV-2.
"This is the first peer-reviewed presentation of our work on BVX-0320 in mice. We expect it to be well received by the scientific community because it is novel and the data convincing," BioVaxys chief medical officer David Berd said in a statement.
Details of the poster presentation are as follows:
Title: A Novel Hapten-Modified SARS-CoV-2 Spike Protein Vaccine (BVX-0320) Induces Antibody and T Cell Responses in a Murine Model
Author: David Berd, BioVaxys Technology Corp.
Poster Viewing Times: October 19, 17:35 Central European Time (CET); October 20, 17:30 CET
ISIRV was founded in 2005 as the first independent international scientific society focused on the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
BioVaxys is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH, a diagnostic for evaluating the presence, or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive